Allianz SE Buys Shares of 34,690 Stevanato Group S.p.A. (NYSE:STVN)

Allianz SE purchased a new position in shares of Stevanato Group S.p.A. (NYSE:STVN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 34,690 shares of the company’s stock, valued at approximately $748,000.

A number of other hedge funds have also made changes to their positions in the stock. Van Berkom & Associates Inc. bought a new stake in Stevanato Group during the fourth quarter worth approximately $39,000. PNC Financial Services Group Inc. boosted its holdings in shares of Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after buying an additional 5,291 shares during the period. US Bancorp DE grew its stake in Stevanato Group by 17.9% in the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock valued at $186,000 after buying an additional 1,295 shares during the last quarter. Marco Investment Management LLC bought a new position in Stevanato Group in the 4th quarter worth $203,000. Finally, Oppenheimer Asset Management Inc. lifted its position in Stevanato Group by 9.7% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,874 shares of the company’s stock worth $281,000 after acquiring an additional 1,141 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on STVN shares. UBS Group lowered their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Bank of America lifted their price target on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of €25.70 ($27.93).

Stevanato Group Price Performance

Shares of STVN stock opened at €20.25 ($22.01) on Monday. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm’s 50 day moving average is €20.90 and its 200-day moving average is €20.60. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.00) and a 1 year high of €32.98 ($35.85). The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN) last released its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.